References

1. ME Mullins, BZ Horowitz, DHJ Linden, GW Smith, RL Norton, J Stump. Life-threatening interactions of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. J Amer Med Assoc 280:157-158, 1998.

2. Anon. Guidance for Industry. Drug metabolism/drug interaction studies in the drug development process: studies in vitro. USFDA 1997:1-10, 1997.

3. M Murray. P450 enzymes. Inhibition mechanism, genetic regulation and effects of liver disease. Clin Pharmacokinet 23:132-146, 1992.

4. FP Guengerich. Role of cytochrome P450 enzymes in drug-drug interactions. In: AP Li, ed. Drug-Drug Interactions: Scientific and Regulatory Perspectives. San Diego: Academic Press, 1997, pp 7-35.

5. C Ioannides. Part II. Cytochrome P450 Families/Subfamilies. In: C Ioannides, ed. Cytochromes P450: Metabolic and Toxicological Aspects. New York: CRC Press, 1996, pp 77-300.

6. M Spatzenegger, W Jaeger. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 27:397-417, 1995.

7. S Rendic, FJ Di Carlo. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 29:413580, 1997.

8. FJ Gonzalez, RC Skoda, S Kimura, M Umeno, UM Zanger, DW Nebert, HV Gel-boin, JP Hardwick, UA Meyer. Characterization of the common genetic defect in human deficient for debrisoquine metabolism. Nature 331:442-446, 1988.

9. SA Wrighton, JC Stevens, GW Becker, M VandenBranden. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylase. Arch Biochem Biophys 306:240-245, 1993.

10. H Furuya, P Fernandez-Salguero, W Gregory, H Taber, A Steward, FJ Gonzalez, JR Idle. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5:389-392, 1995.

11. AD Rodrigues, MJ Kukulka, BW Surber, SB Thomas, JY Uchic, GA Rotert, G Michael, B Thome-Kromer, JM Machinist. Measurement of liver microsomal cyto-chrome (CYP2D6) using [O-meihyZ-14C]-dextromethorphan. Anal Biochem 219: 309-320, 1994.

12. AD Rodrigues, MJ Kukulka, EM Roberts, D Ouellet, TR Rodgers. (O-methyl C-14)naproxen O-demethylase activity in human liver microsomes—evidence for the involvement of CYP1A2 and P4502C9/10. Drug Metab Disp 24:126-136, 1996.

13. AD Rodrigues, BW Surber, Y Yao, SL Wong, EM Roberts. [O-Ethyl 14C]Phena-

0 0

Post a comment